Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 21Other hematologic neoplasm 3Thoracic 2Genitourinary 2Gastrointestinal 2Breast 2Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Classical hematology 1CNS 1

Conditions

Advanced Solid Tumors 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × montanide ISA 51 × Other solid neoplasm × Clear all
NCT01012102 2014-02-20

EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
104 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡